ING Knock-Out RO/ DE000NG86UK1 /
10/10/2024 16:50:25 | Chg.-0.230 | Bid17:17:57 | Ask17:17:57 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
8.610EUR | -2.60% | - Bid Size: - |
- Ask Size: - |
ROCHE I | 368.5116 CHF | 31/12/2078 | Put |
Newsfile Corp
02/10
First Phosphate Corp. communique la publication d'une note de recherche universitaire relative aux g...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
14/06
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire
09/05
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
03/04
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
02/04
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
26/02
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
03/01
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire
03/01
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...
GlobeNewswire
29/12/2023
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
GlobeNewswire
14/12/2023
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibo...